IRVINE, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Mobix Labs, Inc. (Nasdaq: MOBX, “Mobix Labs” or the “Company”), a leading provider of advanced connectivity solutions, today announced the pricing of its previously announced public offering of 30,000,000 shares of its common stock for aggregate gross proceeds of approximately $6.0 million, prior to deducting the placement agent’s fees and other offering expenses. The offering is expected to close on January 7, 2026, subject to satisfaction of customary clos ...

HONG KONG, Dec. 23, 2025 /PRNewswire/ -- Highway Holdings Limited (Nasdaq: HIHO, the "Company" or "Highway Holdings") today announced it has signed a letter of intent ("LOI") with LeMALe Beteiligungs-GmbH ("LeMaLe" or "Seller") to acquire 51% of German-based Regent-Feinbau Adermann GmbH ("Regent-Feinbau") primarily for cash and a smaller amount of the Company's unregistered shares. The proposed acquisition, which targets a close by the end of March 2026, remains subject to the completion of due diligence, ...

Financial Data and Key Metrics Changes - Revenue for Q3 2025 was $32.6 million, reflecting a 432% increase year-over-year and a 101% increase sequentially compared to Q2 2025 [4][18] - Adjusted EBITDA improved sequentially to negative $19.2 million, a $500,000 improvement from Q2 2025 [22] - The company expects revenue to exceed $180 million in fiscal year 2026, with a commitment to achieve positive adjusted EBITDA by the end of Q4 2026 [4][29] Business Line Data and Key Metrics Changes - Platform revenue totaled $19.8 million, up 127% sequentially, driven by strong advertising revenue from Masterworks [20] - Platform Solutions revenue was $12.7 million, up 71% sequentially, supported by strong performance from Masterworks and Midwestern [20][22] - The company anticipates that the acquisition of Westfall Gold will contribute approximately $20 million in revenue in fiscal year 2026 [12][29] Market Data and Key Metrics Changes - The company secured 20 customers expected to contribute over $1 million in annual contract revenue, indicating strong customer momentum [15] - The total addressable market for network capability providers is estimated to be around $60 billion, indicating significant growth potential [58] Company Strategy and Development Direction - Gloo aims to build a leading technology platform serving the faith and flourishing ecosystem, focusing on both churches and network capability providers [5][6] - The company is committed to leveraging strategic acquisitions to enhance its offerings and deepen its market presence [8][29] - Gloo is developing vertical-specific, values-aligned AI capabilities to serve the unique needs of its ecosystem [12][13] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the strong demand across the platform and the positive trajectory of revenue growth [4][25] - The company is focused on building a scalable business while managing costs responsibly, with expectations for significant sequential improvement in adjusted EBITDA starting in Q1 2026 [29][30] - Management highlighted the importance of maintaining discipline in M&A activities to ensure strategic alignment and profitability [78][79] Other Important Information - The company has recently closed two acquisitions, Igniter and XRI Global, which are expected to enhance its capabilities and revenue potential [8][12] - Gloo's IPO added approximately $72.3 million to its balance sheet, significantly strengthening its financial position [24] Q&A Session Summary Question: Can you walk through what the $1 million customers are buying? - Management indicated that the $1 million customers are primarily utilizing Gloo 360 for advanced technology infrastructures and Masterworks for donor engagement [34][35] Question: What factors affect the speed of revenue realization from these deals? - Management noted that proof points in various categories have accelerated deal closures, leading to faster revenue realization [37][38] Question: How much synergy realization is expected from recent acquisitions? - Management stated that synergy realizations will play a significant role in achieving profitability, with ongoing efforts to integrate and optimize across acquisitions [40][42] Question: What investments are being made in Gloo 360? - Management highlighted investments in sales capacity, staff integration from acquired companies, and targeted capabilities in SaaS applications and AI [46][48] Question: How should growth from upsell and conversion be viewed for 2026? - Management indicated a balanced approach between upselling existing customers and acquiring new customers, with a focus on organic growth [67][71]

MISSISSAUGA, Ontario, Dec. 16, 2025 (GLOBE NEWSWIRE) -- Bird Construction Inc. (TSX: BDT) is pleased to announce the award of multiple projects and agreements totaling approximately $1.2 billion, spanning major industrial capital investment projects and a series of significant new and renewed multi-year master service agreements (MSA) with both new and existing clients. Bird’s Industrial Maintenance team, through its existing Indigenous Limited Partnership between Stuart Olson and Infinity Métis Corporation ...

Key Takeaways AbbVie is advancing Rinvoq expansions, tavapadon and PVEK toward multiple potential product launches.Rinvoq label expansions across five indications could add roughly $2B to peak-year sales.Tavapadon and PVEK are under FDA review as AbbVie expands its pipeline via acquisitions.AbbVie (ABBV) has been consistently increasing its R&D investments to support long-term growth across multiple therapeutic areas. The company’s pipeline spans immunology therapies, expanding oncology programs and innovat ...

Summary of TopBuild 2025 Investor Day Company Overview - **Company**: TopBuild (NYSE: BLD) - **Market Cap**: Increased from $3.8 billion in 2017 to $12.5 billion in 2025, more than doubling in value [15] - **Employees**: Over 15,000 employees and more than 450 branches across the U.S. and Canada [15] Key Themes and Strategies 1. **Best-in-Class Industrial Compounder**: TopBuild positions itself as a leading industrial compounder with a clear strategy for profitable growth, driven by strong free cash flow [8] 2. **Market Expansion**: The company has expanded its total addressable market from approximately $16 billion in 2022 to over $90 billion in 2025, focusing on non-discretionary, non-cyclical revenue streams [19][24] 3. **M&A Competency**: TopBuild has completed 24 acquisitions since 2022, totaling 49 acquisitions in the last eight years, contributing to $1.5 billion in revenue [22][19] 4. **Operational Excellence**: Emphasis on leveraging technology and operational excellence to improve customer experience and drive growth [11][12] Financial Performance - **Sales Growth**: Achieved a compounded annual growth rate of over 16% since 2022, maintaining margins in line with long-term targets [19] - **Revenue Diversification**: Increased non-discretionary revenue from 11% in 2022 to 22% in 2025, enhancing revenue resilience [19] Culture and Talent Management 1. **People-First Culture**: TopBuild emphasizes a people-first approach, focusing on employee engagement, safety, and local empowerment [30][31] 2. **Talent Development**: Programs like Manager in Training and leadership academies are in place to develop future leaders, with an 80% success rate of graduates moving into management roles [38][39] 3. **Employee Engagement**: Recent surveys show 85% of employees are engaged, and 93% understand how their roles contribute to the company's success [44] Community Engagement - **Habitat for Humanity Partnership**: TopBuild has a long-standing partnership with Habitat for Humanity, contributing both material and financial resources to support community housing initiatives [2] Future Outlook - **Commercial Roofing Expansion**: TopBuild is entering the commercial roofing market, which is seen as a natural adjacency to its existing insulation business, with a focus on local relationships and operational excellence [24][26] - **Commitment to Safety**: The company has reduced its safety incident rate from 3.58 in 2017 to 1.95 in 2024, reflecting its commitment to employee safety [50] Conclusion TopBuild is positioned for continued growth through strategic market expansion, operational excellence, and a strong focus on its people and community engagement. The company aims to leverage its proven competencies and culture to drive long-term shareholder value.

Core Insights - Boston Scientific (BSX) has been actively pursuing acquisitions to bolster its growth strategy, enhancing its core businesses and entering high-growth adjacent markets [1][5] - The company recently acquired Elutia's BioEnvelope business to prevent post-operative complications for devices like pacemakers and defibrillators, aiming to expand this technology globally [1] - The acquisition of Anrei Medical for approximately $182 million enhances BSX's Endoscopy portfolio, providing more treatment options for physicians [2] - Recent acquisitions, including SoniVie and Intera Oncology, have expanded BSX's offerings in Interventional Cardiology and oncology [3][4] - The acquisition of Bolt Medical aligns with the growth of intravascular lithotripsy therapy, complementing BSX's Cardiovascular portfolio [4] - In Q3 2025, acquisitions contributed 420 basis points to sales, resulting in 15.3% organic revenue growth, exceeding the company's guidance of 12%-14% [5][9] - BSX's stock has increased by 13.1% year-to-date, outperforming the industry growth of 4.9% [8] Acquisitions and Market Position - BSX's recent acquisitions have strengthened its CRM, Endoscopy, Interventional Cardiology, Oncology, and Electrophysiology portfolios [9] - The company has entered into a definitive agreement to acquire Nalu Medical, further enhancing its Neuromodulation division [5][9] - Competitors like Teleflex and GE Healthcare are also active in M&A, with Teleflex acquiring BIOTRONIK's Vascular Intervention business and GE Healthcare acquiring Intelerad for $2.3 billion [6][7] Financial Performance - BSX's valuation is currently high, with a forward five-year Price-to-Earnings (P/E) ratio of 29.57, above its median and industry average [10] - Earnings estimates for BSX are trending upward, with current estimates for the current quarter at $0.78 and for the next year at $3.45 [11][12]

Group 1 - Post Holdings is adopting a nuanced approach to mergers and acquisitions (M&A) to balance opportunities with share buybacks amid declining volumes across its consumer brands, pet food, breakfast cereal, and refrigerated products [1] - The foodservice division of Post Holdings is experiencing growth, contrasting with the overall decline in volumes [1] - CEO Rob Vitale indicated that out-of-home volumes will be supported in fiscal 2026 by the company's highest value products, which are expected to generate significant cash flow for both organic and inorganic growth opportunities [2] Group 2 - In response to a challenging volume landscape in retail products, Post Holdings plans to focus on cost reduction and profitable brand investments while continuing to explore M&A opportunities [3] - Vitale highlighted that the cost of capital has changed dramatically, suggesting a potential inflection point that may increase pressure on the company [4] - The company is shifting its strategy from merely using M&A for growth to a more thoughtful approach that emphasizes quality and innovation rather than just size [5] Group 3 - Vitale disagreed with the notion that Post's portfolio is primarily built around value, asserting that it is centered on choice with a variety of price points [6] - The company aims to innovate towards higher or middle-income consumers, particularly in response to trends affecting lower and middle-income households [6] - Post Holdings plans to capitalize on the rising trend around protein in products like cereals and granola, which are growing faster than other categories [6]

Financial Data and Key Metrics Changes - The company reported a steady increase in the number of franchisee clinics, reaching 258, with a 34-location increase, and the annual customer count expanded to approximately 6.5 million [2] - Financial performance showed signs of recovery, with sales previously affected by restructuring and franchise fees, but now supported by an increase in point-related revenues [3] - Operating income and net income improved due to a decline in racing-related costs, including share-based compensation expenses [3] Business Line Data and Key Metrics Changes - The average revenue per customer visit is recovering due to pricing and promotion initiatives, as well as a multi-brand strategy in the dermatology segment [3] - The company is focusing on enhancing R&D and expanding unique service offerings through the acquisition of Waku, which specializes in regenerative medicine and skincare products [4][5] Market Data and Key Metrics Changes - The company has entered into a partnership with BLEZ ASIA to provide laser treatment in Thailand, aiming to tap into the growing aesthetic medical market [4] - The financial impact of the new BREATH initiative in Thailand is expected to be minimal in the near term, with plans to expand into other Asian countries after proof of concept [10] Company Strategy and Development Direction - The company aims to strengthen its overall competitiveness and achieve sustainable growth through strategic acquisitions and partnerships, particularly in the aesthetic medical field [5][20] - The M&A strategy is divided into domestic and global perspectives, focusing on clinic field acquisitions in Japan and exploring investment opportunities in the US market [20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about maintaining the positive momentum observed in Q3, with expectations for stable financial performance in Q4 and the following year [11][22] - The company is considering providing financial guidance in the near future to address investor needs for revenue and profit expectations [22][26] Other Important Information - The company is working on improving share liquidity through new share issuance and potential share buybacks, acknowledging that the current share price is too low [6][24] - Dividend payments are being considered as a way to attract new investors, although the company prioritizes capital allocation towards strategic initiatives [25] Q&A Session Summary Question: Why was COVID elevated during Q3 2025, and when do you expect a franchise fee division impact to be fully absorbed going forward? - The increase in costs was attributed to medical equipment lease and the consolidation of AHH acquired in Singapore, with financial performance expected to continue improving [8] Question: Could you elaborate on the balance sheet changes during the quarter? - Changes included borrowing for working capital, adjustments in payment terms for related parties, and a decrease in tax debt due to midterm income tax payments [9] Question: What is the expected impact of the new BREATH initiative in Thailand? - The near-term financial impact will be minimal as the company conducts proof of concept for laser treatments, with plans for future expansion into other Asian markets [10] Question: What is the expectation for organic growth going forward? - The company anticipates maintaining the positive momentum from Q3, with expectations for stable financial performance in the upcoming quarters [11] Question: Can you describe the strategic relationship behind acquiring Waku? - The acquisition aims to realize synergies through enhanced sales of Waku products at SBC clinics and joint development of pharmaceutical and medical devices [12][15] Question: Can you comment on the latest status of US business development efforts? - The company is in the phase of understanding the US market and seeking strong partners to leverage its strengths from Japan, with cautious plans for future clinic development [17][18] Question: What are the expectations for M&A going forward? - The M&A strategy will focus on domestic clinic acquisitions and exploring investment opportunities in the global market, particularly in the US [20] Question: How do you plan to improve the liquidity situation? - Plans include increasing free float through new share issuance and potential share buybacks, acknowledging the current low share price [24] Question: Do you think about the dividend going forward? - Dividend payments are considered to attract new investors, but the company prioritizes capital allocation towards growth opportunities [25] Question: Do you have any plan to disclose financial guidance going forward? - The company is considering providing financial guidance in the near future [26]

Financial Data and Key Metrics Changes - The company reported a steady increase in the number of franchisee clinics, reaching 258 clinics, with an annual customer base expanding to approximately 6.5 million [2][3] - Financial performance showed signs of recovery, with operating income and net income benefiting from a decline in racing-related costs and an increase in point-related revenues [3][4] Business Line Data and Key Metrics Changes - The average revenue per customer visit is recovering due to pricing and promotion strategies, as well as a multi-brand strategy in the dermatology segment [3] - The company is focusing on enhancing R&D capabilities through the acquisition of Waku, which specializes in regenerative medicine and skincare products [4][5] Market Data and Key Metrics Changes - The company has entered into a partnership with BLEZ ASIA to provide laser treatment in Thailand, aiming to tap into the growing aesthetic medical market [4] - The company is exploring proof of concept (POC) initiatives in Thailand, with plans to expand into other Asian markets like Malaysia and Indonesia [11] Company Strategy and Development Direction - The company aims to strengthen its overall competitiveness and achieve sustainable growth through strategic partnerships and acquisitions, particularly in the aesthetic medical and clinical industries [20] - The U.S. market entry strategy involves forming strong partnerships and leveraging learnings from the Japanese market, while being cautious about direct replication of the business model [17][18] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about maintaining positive momentum in financial performance, expecting stable growth in Q4 and the following year [12][21] - The company is considering providing financial guidance in the near future to address investor needs for revenue and profit expectations [21][25] Other Important Information - The company is working on improving liquidity through measures such as new share issuance and potential share buybacks, acknowledging the current low share price [6][23] - Dividend payments are being considered as a way to attract new investors, although the focus remains on capital allocation for strategic initiatives [24] Q&A Session Summary Question: Why was COVID elevated during Q3 2025, and when do you expect a Franchise Fee Division impact to be fully absorbed going forward? - The increase in costs was attributed to medical equipment lease and the consolidation of AHH acquired in Singapore, with expectations of continued positive trends [9] Question: Could you elaborate on the Balance Sheet changes during the quarter? - Changes included borrowing for working capital, adjustments in payment terms for related parties, and a decrease in tax debt due to midterm income tax payments [10] Question: What is your expectation for organic growth going forward for both breadth and revenue? - The company expects to maintain positive momentum seen in Q3, with stable financial performance anticipated in Q4 and next year [12] Question: Could you describe the strategic relationship behind acquiring Waku? - The acquisition aims to realize synergies through enhanced sales of Waku products at SBC clinics and joint development of pharmaceutical and medical devices [15][16] Question: Can you comment on the latest status of your U.S. business development efforts? - The company is in a phase of understanding the U.S. market and seeking strong partners, with plans for future growth and expansion once comfortable [17][18] Question: What do you mean by more stable financial performance in Q4 and 2026? - Management confirmed expectations for revenue growth but could not provide specific numbers at this time [21] Question: How do you think about improving the liquidity situation? - The company is considering new share issues and share buybacks to increase free float and address low share prices [23] Question: Do you have any plan to disclose financial guidance or performance guidance going forward? - The company is actively considering providing financial guidance in the near future [25]